Cargando…

Stereotactic radiotherapy with focal boost for intermediate and high-risk prostate cancer: Initial results of the SPARC trial

INTRODUCTION: Dose escalation to dominant intraprostatic lesions (DILs) is a novel method to increase the therapeutic ratio in localised prostate cancer. The Stereotactic Prostate Augmented Radiotherapy with Cyberknife (SPARC) trial was designed to determine the feasibility of a focal boost defined...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nicholls, Luke, Suh, Yae-eun, Chapman, Ewan, Henderson, Daniel, Jones, Caroline, Morrison, Kirsty, Sohaib, Aslam, Taylor, Helen, Tree, Alison, van As, Nicholas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7591551/ https://www.ncbi.nlm.nih.gov/pubmed/33145444 http://dx.doi.org/10.1016/j.ctro.2020.10.004

Ejemplares similares

Prostate stereotactic body radiotherapy with simultaneous integrated boost: which is the best planning method?
por: Tree, Alison, et al.
Publicado: (2013)

Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results
por: Aluwini, Shafak, et al.
Publicado: (2013)

Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer
por: Anwar, Mekhail, et al.
Publicado: (2016)

Stereotactic ablative body radiotherapy boost for cervical cancer when brachytherapy boost is not feasible
por: Lee, Tae Hoon, et al.
Publicado: (2021)

Use of focal radiotherapy boost for prostate cancer: radiation oncologists’ perspectives and perceived barriers to implementation
por: Zhong, Allison Y., et al.
Publicado: (2023)

Stereotactic Body Radiotherapy for Primary Prostate Cancer
por: Kothari, Gargi, et al.
Publicado: (2018)

Dosimetric Implications of Computerised Tomography-Only versus Magnetic Resonance-Fusion Contouring in Stereotactic Body Radiotherapy for Prostate Cancer
por: Henderson, Daniel R., et al.
Publicado: (2018)

Stereotactic body radiotherapy for bone oligometastatic disease in prostate cancer
por: Patel, Priyanka H., et al.
Publicado: (2019)

Phase 2 Multicenter Study of Gantry-Based Stereotactic Radiotherapy Boost for Intermediate and High Risk Prostate Cancer (PROMETHEUS)
por: Pryor, David, et al.
Publicado: (2019)

SPARC's Initiative
por: Alison Buckholtz
Publicado: (2002)

Lung Stereotactic Body Radiotherapy (SBRT) Using Spot-Scanning Proton Arc (SPArc) Therapy: A Feasibility Study
por: Liu, Gang, et al.
Publicado: (2021)

Focal HDR brachytherapy boost to stereotactic radiotherapy (fBTsRT) for prostate cancer: a phase II randomized controlled trial
por: Belliveau, C., et al.
Publicado: (2022)

Hypofractionated stereotactic body radiotherapy in low- and intermediate-risk prostate carcinoma
por: Kim, Hun Jung, et al.
Publicado: (2016)

Dosimetric Comparison of Upfront Boosting With Stereotactic Radiosurgery Versus Intraoperative Radiotherapy for Glioblastoma
por: Sarria, Gustavo R., et al.
Publicado: (2021)

Stereotactic Radiotherapy Boost in Treatment of Persistent Periocular Sebaceous Carcinoma after Surgery
por: Polanowski, Paweł, et al.
Publicado: (2023)

CyberKnife multisession stereotactic radiosurgery and hypofractionated stereotactic radiotherapy for perioptic meningiomas: intermediate-term results and radiobiological considerations
por: Conti, Alfredo, et al.
Publicado: (2015)

Brachytherapy Versus Stereotactic Body Radiotherapy for Cervical Cancer Boost: A Dosimetric Comparison
por: Dahbi, Zineb, et al.
Publicado: (2023)

The Early Result of Whole Pelvic Radiotherapy and Stereotactic Body Radiotherapy Boost for High-Risk Localized Prostate Cancer
por: Lin, Yu-Wei, et al.
Publicado: (2014)

Automated treatment planning of prostate stereotactic body radiotherapy with focal boosting on a fast‐rotating O‐ring linac: Plan quality comparison with C‐arm linacs
por: De Roover, Robin, et al.
Publicado: (2021)

Effects of two different radiotherapies for craniopharyngiomas using stereotactic radiosurgery/ stereotactic radiotherapy or fractionated stereotactic radiotherapy
por: Kamogawa, Misaki, et al.
Publicado: (2022)

Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial
por: Brand, Douglas H, et al.
Publicado: (2019)

Focal Boost in Prostate Cancer Radiotherapy: A Review of Planning Studies and Clinical Trials
por: Zhao, Yutong, et al.
Publicado: (2023)

High-dose stereotactic radiotherapy boost in the treatment of squamous cell carcinoma of the head and neck region
por: Polanowski, Paweł, et al.
Publicado: (2022)

Feasibility of a simultaneously integrated boost concept for hypofractionated stereotactic radiotherapy of unresected brain metastases
por: Kornhuber, Christine, et al.
Publicado: (2023)

Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer
por: Kishan, Amar U., et al.
Publicado: (2019)

Whole Pelvic Radiotherapy With Stereotactic Body Radiotherapy Boost vs. Conventionally Fractionated Radiotherapy for Patients With High or Very High-Risk Prostate Cancer
por: Wang, Shih-Chang, et al.
Publicado: (2020)

Stereotactic prostate focal reirradiation therapy for local recurrence: preliminary results of Hartmann Oncology Radiotherapy Group
por: Scher, Nathaniel, et al.
Publicado: (2019)

PROstate Multicentre External beam radioTHErapy Using a Stereotactic boost: the PROMETHEUS study protocol
por: Richardson, Matthew, et al.
Publicado: (2018)

Successful Treatment of Adenoid Cystic Carcinoma with the Application of a High-Dose Stereotactic Body Radiotherapy Boost
por: Polanowski, Paweł, et al.
Publicado: (2021)

Stereotactic radiosurgery and stereotactic radiotherapy for brain metastases
por: Halasz, Lia M., et al.
Publicado: (2013)

Long-term outcome and toxicity of hypofractionated stereotactic body radiotherapy as a boost treatment for head and neck cancer: the importance of boost volume assessment
por: Lee, Dong Soo, et al.
Publicado: (2012)

Stereotactic Radiotherapy for Oligometastasis
por: Otake, Sotaro, et al.
Publicado: (2019)

Radiobiology of stereotactic radiotherapy
por: Mangoni, Monica, et al.
Publicado: (2022)

Prostate-specific antigen kinetics after stereotactic body radiotherapy as monotherapy or boost after whole pelvic radiotherapy for localized prostate cancer
por: Kim, Hun Jung, et al.
Publicado: (2015)

Evolution of dental tissue mineralization: an analysis of the jawed vertebrate SPARC and SPARC-L families
por: Enault, Sébastien, et al.
Publicado: (2018)

Hypofractionated stereotactic boost in intermediate risk prostate carcinoma: Preliminary results of a multicenter phase II trial (CKNO-PRO)
por: Pasquier, David, et al.
Publicado: (2017)

Prostate stereotactic body radiotherapy: quantifying intra-fraction motion and calculating margins using the new BIR geometric uncertainties in daily online IGRT recommendations
por: McNeice, Joseph M, et al.
Publicado: (2023)

A Multicenter Phase 2 Study of Ultrahypofractionated Stereotactic Boost After External Beam Radiotherapy in Intermediate-risk Prostate Carcinoma: A Very Long-term Analysis of the CKNO-PRO Trial
por: Pasquier, David, et al.
Publicado: (2023)

IMRT with Stereotactic Body Radiotherapy Boost for High Risk Malignant Salivary Gland Malignancies: A Case Series
por: Karam, Sana D., et al.
Publicado: (2014)

Partial stereotactic ablative boost radiotherapy in bulky non-small cell lung cancer: a retrospective study
por: Bai, Yun, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_itl27v9i5ba792i8i2am5tn8b9